{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,5]],"date-time":"2026-09-05T23:11:33Z","timestamp":1788649893111,"version":"build-2803163510"},"reference-count":48,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2024,10,15]],"date-time":"2024-10-15T00:00:00Z","timestamp":1728950400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2024,10,15]],"date-time":"2024-10-15T00:00:00Z","timestamp":1728950400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/100000054","name":"National Cancer Institute","doi-asserted-by":"publisher","award":["T32 CA113263"],"award-info":[{"award-number":["T32 CA113263"]}],"id":[{"id":"10.13039\/100000054","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000054","name":"National Cancer Institute","doi-asserted-by":"publisher","award":["R01 CA277664"],"award-info":[{"award-number":["R01 CA277664"]}],"id":[{"id":"10.13039\/100000054","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000054","name":"National Cancer Institute","doi-asserted-by":"publisher","award":["P30 CA047904"],"award-info":[{"award-number":["P30 CA047904"]}],"id":[{"id":"10.13039\/100000054","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000054","name":"National Cancer Institute","doi-asserted-by":"publisher","award":["PAR-20-043"],"award-info":[{"award-number":["PAR-20-043"]}],"id":[{"id":"10.13039\/100000054","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000054","name":"National Cancer Institute","doi-asserted-by":"publisher","award":["F32 CA287961"],"award-info":[{"award-number":["F32 CA287961"]}],"id":[{"id":"10.13039\/100000054","id-type":"DOI","asserted-by":"publisher"}]},{"name":"University of Pittsburgh Funds","award":["University of Pittsburgh Funds"],"award-info":[{"award-number":["University of Pittsburgh Funds"]}]},{"DOI":"10.13039\/100000915","name":"Richard King Mellon Foundation","doi-asserted-by":"publisher","award":["Mellon Scholar Award"],"award-info":[{"award-number":["Mellon Scholar Award"]}],"id":[{"id":"10.13039\/100000915","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Marjory K. Harmer endowment for Research in Pediatric Pathology","award":["Marjory K. Harmer endowment for Research in Pediatric Pathology"],"award-info":[{"award-number":["Marjory K. Harmer endowment for Research in Pediatric Pathology"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Transl Med"],"abstract":"<jats:title>Abstract<\/jats:title><jats:sec>\n                <jats:title>Background<\/jats:title>\n                <jats:p>Surgical resection is integral for the treatment of neuroblastoma, the most common extracranial solid malignancy in children. Safely locating and resecting primary tumor and remote deposits of disease remains a significant challenge, resulting in high rates of complications and incomplete surgery, worsening outcomes. Intraoperative molecular imaging (IMI) uses targeted radioactive or fluorescent tracers to identify and visualize tumors intraoperatively. GD2 was selected as an IMI target, as it is highly overexpressed in neuroblastoma and minimally expressed in normal tissue.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Methods<\/jats:title>\n                <jats:p>GD2 expression in neuroblastoma cell lines was measured by flow cytometry. DTPA and IRDye<jats:sup>\u00ae<\/jats:sup> 800CW were conjugated to anti-GD2 antibody to generate DTPA-\u03b1GD2-IR800. Binding affinity (Kd) of the antibody and the non-radiolabeled tracer were then measured by ELISA assay. Human neuroblastoma SK-N-BE(2) cells were surgically injected into the left adrenal gland of 3.5-5-week-old nude mice and the orthotopic xenograft tumors grew for 5 weeks. <jats:sup>111<\/jats:sup>In-\u03b1GD2-IR800 or isotype control tracer was administered via tail vein injection. After 4 and 6 days, mice were euthanized and gamma and fluorescence biodistributions were measured using a gamma counter and ImageJ analysis of acquired SPY-PHI fluorescence images of resected organs (including tumor, contralateral adrenal, kidneys, liver, muscle, blood, and others). Organ uptake was compared by one-way ANOVA (with a separate analysis for each tracer\/day combination), and if significant, Sidak\u2019s multiple comparison test was used to compare the uptake of each organ to the tumor. Handheld tools were also used to detect and visualize tumor in situ, and to assess for residual disease following non-guided resection.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Results<\/jats:title>\n                <jats:p><jats:sup>111<\/jats:sup>In-\u03b1GD2-IR800 was successfully synthesized with 0.75-2.0 DTPA and 2\u20133 IRDye<jats:sup>\u00ae<\/jats:sup> 800CW per antibody and retained adequate antigen-binding (K<jats:sub>d<\/jats:sub> = 2.39 nM for aGD2 vs. 21.31 nM for DTPA-aGD2-IR800). The anti-GD2 tracer demonstrated antigen-specific uptake in mice with human neuroblastoma xenografts (gamma biodistribution tumor-to-blood ratios of 3.87 and 3.88 on days 4 and 6 with anti-GD2 tracer), while isotype control tracer did not accumulate (0.414 and 0.514 on days 4 and 6). Probe accumulation in xenografts was detected and visualized using widely available operative tools (Neoprobe<jats:sup>\u00ae<\/jats:sup> and SPY-PHI camera) and facilitated detection ofputative residual disease in the resection cavity following unguided resection.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Conclusions<\/jats:title>\n                <jats:p>We have developed a dual-labeled anti-GD2 antibody-based tracer that incorporates In-111 and IRDye<jats:sup>\u00ae<\/jats:sup> 800CW for radio- and fluorescence-guided surgery, respectively. The tracer adequately binds to GD2, specifically accumulates in GD2-expressing xenograft tumors, and enables tumor visualization with a hand-held NIR camera. These results encourage the development of <jats:sup>111<\/jats:sup>In-\u03b1GD2-IR800 for future use in children with neuroblastoma, with the goal of improving patient safety, completeness of resection, and overall patient outcomes.<\/jats:p>\n              <\/jats:sec>","DOI":"10.1186\/s12967-024-05728-0","type":"journal-article","created":{"date-parts":[[2024,10,15]],"date-time":"2024-10-15T10:02:26Z","timestamp":1728986546000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":9,"title":["Dual-labeled anti-GD2 targeted probe for intraoperative molecular imaging of neuroblastoma"],"prefix":"10.1186","volume":"22","author":[{"given":"Lauren Taylor","family":"Rosenblum","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"ReidAnn E.","family":"Sever","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ryan","family":"Gilbert","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David","family":"Guerrero","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sarah R.","family":"Vincze","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dominic M.","family":"Menendez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peggy A.","family":"Birikorang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mikayla R.","family":"Rodgers","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ambika Parmar","family":"Jaswal","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alexander C.","family":"Vanover","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joseph D.","family":"Latoche","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Angel G.","family":"Cortez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kathryn E.","family":"Day","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lesley M.","family":"Foley","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chaim T.","family":"Sneiderman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Itay","family":"Raphael","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"T. Kevin","family":"Hitchens","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jessie R.","family":"Nedrow","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gary","family":"Kohanbash","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"W. Barry","family":"Edwards","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8803-8553","authenticated-orcid":false,"given":"Marcus M.","family":"Malek","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2024,10,15]]},"reference":[{"key":"5728_CR1","doi-asserted-by":"crossref","unstructured":"Siegel RL, Miller KD, Fuchs HE, Jemal A, Cancer Statistics. 2021. CA Cancer J Clin. 2021;71(1):7\u201333. Epub 2021\/01\/13. doi: 10.3322\/caac.21654. PubMed PMID: 33433946.","DOI":"10.3322\/caac.21654"},{"issue":"2","key":"5728_CR2","doi-asserted-by":"publisher","first-page":"289","DOI":"10.1200\/JCO.2008.16.6785","volume":"27","author":"SL Cohn","year":"2009","unstructured":"Cohn SL, Pearson ADJ, London WB, et al. The International Neuroblastoma Risk Group (INRG) classification system: an INRG Task Force Report. J Clin Oncol. 2009;27(2):289\u201397. https:\/\/doi.org\/10.1200\/JCO.2008.16.6785.","journal-title":"J Clin Oncol"},{"issue":"1","key":"5728_CR3","doi-asserted-by":"publisher","first-page":"35","DOI":"10.1016\/S1470-2045(13)70548-5","volume":"15","author":"G Gatta","year":"2014","unstructured":"Gatta G, Botta L, Rossi S, et al. Childhood cancer survival in Europe 1999\u20132007: results of EUROCARE-5\u2014a population-based study. Lancet Oncol. 2014;15(1):35\u201347. https:\/\/doi.org\/10.1016\/S1470-2045(13)70548-5.","journal-title":"Lancet Oncol"},{"key":"5728_CR4","doi-asserted-by":"publisher","first-page":"47","DOI":"10.1016\/j.ejca.2019.09.025","volume":"124","author":"ML Tas","year":"2020","unstructured":"Tas ML, Reedijk AMJ, Karim-Kos HE, et al. Neuroblastoma between 1990 and 2014 in the Netherlands: increased incidence and improved survival of high-risk neuroblastoma. Eur J Cancer. 2020;124:47\u201355. https:\/\/doi.org\/10.1016\/j.ejca.2019.09.025.","journal-title":"Eur J Cancer"},{"issue":"10","key":"5728_CR5","doi-asserted-by":"publisher","first-page":"889","DOI":"10.1080\/14737140.2017.1364995","volume":"17","author":"S Sait","year":"2017","unstructured":"Sait S, Modak S. Anti-GD2 immunotherapy for neuroblastoma. Expert Rev Anticancer Ther. 2017;17(10):889\u2013904. https:\/\/doi.org\/10.1080\/14737140.2017.1364995.","journal-title":"Expert Rev Anticancer Ther"},{"key":"5728_CR6","doi-asserted-by":"publisher","first-page":"1526","DOI":"10.1016\/S0022-3468(98)90490-0","volume":"33","author":"A Ca\u00f1ete","year":"1998","unstructured":"Ca\u00f1ete A, Jovani C, Lopez A, Costa E, Segarra V, Fern\u00e1ndez JM, et al. Surgical treatment for neuroblastoma: complications during 15 years\u2019 experience. J Pediatr Surg. 1998;33:1526\u201330.","journal-title":"J Pediatr Surg"},{"key":"5728_CR7","doi-asserted-by":"publisher","first-page":"2902","DOI":"10.1200\/JCO.19.03117","volume":"38","author":"K Holmes","year":"2020","unstructured":"Holmes K, P\u00f6tschger U, Pearson ADJ, Sarnacki S, Cecchetto G, Gomez-Chacon J, et al. Influence of surgical excision on the survival of patients with stage 4 high-risk neuroblastoma: a report from the HR-NBL1\/SIOPEN study. J Clin Oncol. 2020;38:2902\u201315.","journal-title":"J Clin Oncol"},{"key":"5728_CR8","doi-asserted-by":"publisher","first-page":"208","DOI":"10.1200\/JCO.2016.67.2642","volume":"35","author":"D von Allmen","year":"2017","unstructured":"von Allmen D, Davidoff AM, London WB, Van Ryn C, Haas-Kogan DA, Kreissman SG, et al. Impact of extent of resection on Local Control and survival in patients from the COG A3973 study with high-risk neuroblastoma. J Clin Oncol. 2017;35:208\u201316.","journal-title":"J Clin Oncol"},{"key":"5728_CR9","doi-asserted-by":"publisher","first-page":"392","DOI":"10.1001\/archsurg.1992.01420040034005","volume":"127","author":"DL Morton","year":"1992","unstructured":"Morton DL, Wen D-R, Wong JH, Economou JS, Cagle LA, Storm FK, et al. Technical Details of Intraoperative Lymphatic Mapping for Early Stage Melanoma. Arch Surg. 1992;127:392\u20139.","journal-title":"Arch Surg"},{"key":"5728_CR10","doi-asserted-by":"publisher","first-page":"675","DOI":"10.1007\/s10549-011-1665-1","volume":"129","author":"Z Wang","year":"2011","unstructured":"Wang Z, Wu L-C, Chen J-Q. Sentinel lymph node biopsy compared with axillary lymph node dissection in early breast cancer: a meta-analysis. Breast Cancer Res Treat. 2011;129:675\u201389.","journal-title":"Breast Cancer Res Treat"},{"issue":"8","key":"5728_CR11","doi-asserted-by":"publisher","first-page":"711","DOI":"10.1080\/17434440.2019.1642104","volume":"16","author":"MN Van Oosterom","year":"2019","unstructured":"Van Oosterom MN, Rietbergen DDD, Welling MM, Van Der Poel HG, Maurer T, Van Leeuwen FWB. Recent advances in nuclear and hybrid detection modalities for image-guided surgery. Expert Rev Med Dev. 2019;16(8):711\u201334. https:\/\/doi.org\/10.1080\/17434440.2019.1642104.","journal-title":"Expert Rev Med Dev"},{"key":"5728_CR12","unstructured":"Commissioner O of the. FDA Approves New Imaging Drug to Help Identify Ovarian Cancer Lesions [Internet]. FDA. FDA. 2021 [cited 2023 Mar 29]. https:\/\/www.fda.gov\/news-events\/press-announcements\/fda-approves-new-imaging-drug-help-identify-ovarian-cancer-lesions"},{"key":"5728_CR13","doi-asserted-by":"crossref","unstructured":"Tanyi JL, Randall LM, Chambers SK, Butler KA, Winer IS, Langstraat CL et al. A phase III study of pafolacianine injection (OTL38) for intraoperative imaging of Folate receptor\u2013positive ovarian Cancer (study 006). J Clin Oncol. 2023;41(2):276\u201384.","DOI":"10.1200\/JCO.22.00291"},{"issue":"3","key":"5728_CR14","doi-asserted-by":"publisher","first-page":"181","DOI":"10.1016\/S2468-1253(17)30395-3","volume":"3","author":"LSF Boogerd","year":"2018","unstructured":"Boogerd LSF, Hoogstins CES, Schaap DP, et al. Safety and effectiveness of SGM-101, a fluorescent antibody targeting carcinoembryonic antigen, for intraoperative detection of colorectal cancer: a dose-escalation pilot study. Lancet Gastroenterol Hepatol. 2018;3(3):181\u201391. https:\/\/doi.org\/10.1016\/S2468-1253(17)30395-3.","journal-title":"Lancet Gastroenterol Hepatol"},{"issue":"17","key":"5728_CR15","doi-asserted-by":"publisher","first-page":"5144","DOI":"10.1158\/0008-5472.CAN-18-0878","volume":"78","author":"RW Gao","year":"2018","unstructured":"Gao RW, Teraphongphom NT, van den Berg NS, et al. Determination of Tumor margins with Surgical Specimen Mapping using Near-Infrared fluorescence. Cancer Res. 2018;78(17):5144\u201354. https:\/\/doi.org\/10.1158\/0008-5472.CAN-18-0878.","journal-title":"Cancer Res"},{"key":"5728_CR16","doi-asserted-by":"publisher","first-page":"1150","DOI":"10.1016\/j.athoracsur.2020.09.037","volume":"112","author":"S Gangadharan","year":"2021","unstructured":"Gangadharan S, Sarkaria IN, Rice D, Murthy S, Braun J, Kucharczuk J, et al. Multiinstitutional Phase 2 Clinical Trial of Intraoperative Molecular Imaging of Lung Cancer. Ann Thorac Surg. 2021;112:1150\u20139.","journal-title":"Ann Thorac Surg"},{"key":"5728_CR17","doi-asserted-by":"publisher","first-page":"2161","DOI":"10.7150\/thno.23335","volume":"8","author":"MC Hekman","year":"2018","unstructured":"Hekman MC, Rijpkema M, Muselaers CH, Oosterwijk E, Hulsbergen-Van de Kaa CA, Boerman OC, et al. Tumor-targeted dual-modality imaging to improve intraoperative visualization of Clear Cell Renal Cell Carcinoma: A First in Man Study. Theranostics. 2018;8:2161\u201370.","journal-title":"Theranostics"},{"key":"5728_CR18","doi-asserted-by":"publisher","first-page":"706","DOI":"10.2967\/jnumed.116.185470","volume":"58","author":"MCH Hekman","year":"2017","unstructured":"Hekman MCH, Rijpkema M, Bos DL, Oosterwijk E, Goldenberg DM, Mulders PFA, et al. Detection of Micrometastases using SPECT\/Fluorescence dual-modality imaging in a CEA-Expressing Tumor Model. J Nucl Med. 2017;58:706\u201310.","journal-title":"J Nucl Med"},{"key":"5728_CR19","doi-asserted-by":"publisher","first-page":"459","DOI":"10.2967\/jnumed.118.213488","volume":"60","author":"SH Vargas","year":"2019","unstructured":"Vargas SH, Ghosh SC, Azhdarinia A. New Developments in Dual-labeled Molecular Imaging agents. J Nucl Med. 2019;60:459\u201365.","journal-title":"J Nucl Med"},{"issue":"571","key":"5728_CR20","doi-asserted-by":"publisher","first-page":"eabd6169","DOI":"10.1126\/scitranslmed.abd6169","volume":"12","author":"K Straathof","year":"2020","unstructured":"Straathof K, Flutter B, Wallace R, et al. Antitumor activity without on-target off-tumor toxicity of GD2\u2013chimeric antigen receptor T cells in patients with neuroblastoma. Sci Transl Med. 2020;12(571):eabd6169. https:\/\/doi.org\/10.1126\/scitranslmed.abd6169.","journal-title":"Sci Transl Med"},{"issue":"12","key":"5728_CR21","doi-asserted-by":"publisher","first-page":"3112","DOI":"10.1158\/0008-5472.CAN-18-3340","volume":"79","author":"ER Butch","year":"2019","unstructured":"Butch ER, Mead PE, Amador Diaz V, et al. Positron Emission Tomography detects in vivo expression of Disialoganglioside GD2 in Mouse models of primary and metastatic osteosarcoma. Cancer Res. 2019;79(12):3112\u201324. https:\/\/doi.org\/10.1158\/0008-5472.CAN-18-3340.","journal-title":"Cancer Res"},{"issue":"5","key":"5728_CR22","doi-asserted-by":"publisher","first-page":"909","DOI":"10.3892\/ijo.3.5.909","volume":"3","author":"G Lammie","year":"1993","unstructured":"Lammie G, Cheung N, Gerald W, Rosenblum M, Cordoncardo C, GANGLIOSIDE GD(2) EXPRESSION IN THE HUMAN NERVOUS-SYSTEM AND IN NEUROBLASTOMAS - AN IMMUNOHISTOCHEMICAL STUDY. Int J Oncol. 1993;3(5):909\u201315. https:\/\/doi.org\/10.3892\/ijo.3.5.909.","journal-title":"Int J Oncol"},{"issue":"9","key":"5728_CR23","doi-asserted-by":"publisher","first-page":"2221","DOI":"10.3390\/cancers14092221","volume":"14","author":"HN Rinehardt","year":"2022","unstructured":"Rinehardt HN, Longo S, Gilbert R, et al. Handheld PET probe for Pediatric Cancer surgery. Cancers. 2022;14(9):2221. https:\/\/doi.org\/10.3390\/cancers14092221.","journal-title":"Cancers"},{"issue":"6","key":"5728_CR24","doi-asserted-by":"publisher","first-page":"540","DOI":"10.1111\/cts.12567","volume":"11","author":"M Ovacik","year":"2018","unstructured":"Ovacik M, Lin K. Tutorial on monoclonal antibody pharmacokinetics and its considerations in Early Development. Clin Transl Sci. 2018;11(6):540\u201352. https:\/\/doi.org\/10.1111\/cts.12567.","journal-title":"Clin Transl Sci"},{"key":"5728_CR25","first-page":"2461","volume":"58","author":"AC Croce","year":"2014","unstructured":"Croce AC, Bottiroli G. Autofluorescence spectroscopy and imaging: a Tool for Biomedical Research and diagnosis. Eur J Histochem EJH. 2014;58:2461.","journal-title":"Eur J Histochem EJH"},{"key":"5728_CR26","doi-asserted-by":"publisher","first-page":"5144","DOI":"10.1158\/0008-5472.CAN-18-0878","volume":"78","author":"RW Gao","year":"2018","unstructured":"Gao RW, Teraphongphom NT, van den Berg NS, Martin BA, Oberhelman NJ, Divi V, et al. Determination of Tumor margins with Surgical Specimen Mapping using Near-Infrared fluorescence. Cancer Res. 2018;78:5144\u201354.","journal-title":"Cancer Res"},{"issue":"1","key":"5728_CR27","doi-asserted-by":"publisher","first-page":"1","DOI":"10.2174\/1874471011104010001","volume":"4","author":"A Nalla","year":"2011","unstructured":"Nalla A, Buch I, Hesse B. Easy and efficient 111Indium labeling of long-term stored DTPA conjugated protein. Curr Radiopharmaceuticals. 2011;4(1):1\u20134.","journal-title":"Curr Radiopharmaceuticals"},{"issue":"11","key":"5728_CR28","doi-asserted-by":"publisher","first-page":"1772","DOI":"10.2967\/jnumed.112.104208","volume":"53","author":"AL V\u0101vere","year":"2012","unstructured":"V\u0101vere AL, Butch ER, Dearling JLJ, et al. 64Cu-p-NH2-Bn-DOTA-hu14.18K322A, a PET Radiotracer Targeting Neuroblastoma and Melanoma. J Nucl Med. 2012;53(11):1772\u20138. https:\/\/doi.org\/10.2967\/jnumed.112.104208.","journal-title":"J Nucl Med"},{"issue":"19","key":"5728_CR29","doi-asserted-by":"publisher","first-page":"4258","DOI":"10.1158\/0008-5472.CAN-20-1344","volume":"80","author":"F Nguyen","year":"2020","unstructured":"Nguyen F, Guan P, Guerrero DT, et al. Structural optimization and enhanced prodrug-mediated delivery overcomes Camptothecin Resistance in High-Risk Solid tumors. Cancer Res. 2020;80(19):4258\u201365. https:\/\/doi.org\/10.1158\/0008-5472.CAN-20-1344.","journal-title":"Cancer Res"},{"key":"5728_CR30","doi-asserted-by":"publisher","first-page":"685","DOI":"10.1007\/s11307-019-01427-1","volume":"22","author":"S Nigam","year":"2020","unstructured":"Nigam S, McCarl L, Kumar R, Edinger RS, Kurland BF, Anderson CJ, et al. Preclinical ImmunoPET imaging of Glioblastoma-infiltrating myeloid cells using Zirconium-89 labeled Anti-CD11b antibody. Mol Imaging Biol. 2020;22:685\u201394.","journal-title":"Mol Imaging Biol"},{"key":"5728_CR31","doi-asserted-by":"publisher","first-page":"4258","DOI":"10.1158\/0008-5472.CAN-20-1344","volume":"80","author":"F Nguyen","year":"2020","unstructured":"Nguyen F, Guan P, Guerrero DT, Kolla V, Naraparaju K, Perry LM, et al. Structural optimization and enhanced prodrug-mediated delivery overcomes Camptothecin Resistance in High-Risk Solid tumors. Cancer Res. 2020;80:4258\u201365.","journal-title":"Cancer Res"},{"issue":"25","key":"5728_CR32","doi-asserted-by":"publisher","first-page":"2902","DOI":"10.1200\/JCO.19.03117","volume":"38","author":"K Holmes","year":"2020","unstructured":"Holmes K, P\u00f6tschger U, Pearson ADJ, et al. Influence of surgical excision on the survival of patients with stage 4 high-risk neuroblastoma: a report from the HR-NBL1\/SIOPEN study. J Clin Oncol. 2020;38(25):2902\u201315. https:\/\/doi.org\/10.1200\/JCO.19.03117.","journal-title":"J Clin Oncol"},{"issue":"6","key":"5728_CR33","doi-asserted-by":"publisher","first-page":"2169","DOI":"10.1200\/jco.1998.16.6.2169","volume":"16","author":"AL Yu","year":"1998","unstructured":"Yu AL, Uttenreuther-Fischer MM, Huang CS, et al. Phase I trial of a human-mouse chimeric anti-disialoganglioside monoclonal antibody ch14.18 in patients with refractory neuroblastoma and osteosarcoma. J Clin Oncol. 1998;16(6):2169\u201380. https:\/\/doi.org\/10.1200\/jco.1998.16.6.2169.","journal-title":"J Clin Oncol"},{"issue":"2","key":"5728_CR34","doi-asserted-by":"publisher","first-page":"208","DOI":"10.1200\/JCO.2016.67.2642","volume":"35","author":"D von Allmen","year":"2017","unstructured":"von Allmen D, Davidoff AM, London WB, et al. Impact of extent of resection on Local Control and survival in patients from the COG A3973 study with high-risk neuroblastoma. J Clin Oncol. 2017;35(2):208\u201316. https:\/\/doi.org\/10.1200\/JCO.2016.67.2642.","journal-title":"J Clin Oncol"},{"issue":"10","key":"5728_CR35","doi-asserted-by":"publisher","first-page":"1526","DOI":"10.1016\/S0022-3468(98)90490-0","volume":"33","author":"A Ca\u00f1ete","year":"1998","unstructured":"Ca\u00f1ete A, Jovani C, Lopez A, et al. Surgical treatment for neuroblastoma: complications during 15 years\u2019 experience. J Pediatr Surg. 1998;33(10):1526\u201330. https:\/\/doi.org\/10.1016\/S0022-3468(98)90490-0.","journal-title":"J Pediatr Surg"},{"issue":"17","key":"5728_CR36","doi-asserted-by":"publisher","first-page":"5323","DOI":"10.1158\/1078-0432.CCR-09-0737","volume":"15","author":"MA Cheever","year":"2009","unstructured":"Cheever MA, Allison JP, Ferris AS, et al. The prioritization of Cancer antigens: a National Cancer Institute Pilot Project for the Acceleration of Translational Research. Clin Cancer Res. 2009;15(17):5323\u201337. https:\/\/doi.org\/10.1158\/1078-0432.CCR-09-0737.","journal-title":"Clin Cancer Res"},{"issue":"3","key":"5728_CR37","doi-asserted-by":"publisher","first-page":"675","DOI":"10.1007\/s10549-011-1665-1","volume":"129","author":"Z Wang","year":"2011","unstructured":"Wang Z, Wu LC, Chen JQ. Sentinel lymph node biopsy compared with axillary lymph node dissection in early breast cancer: a meta-analysis. Breast Cancer Res Treat. 2011;129(3):675\u201389. https:\/\/doi.org\/10.1007\/s10549-011-1665-1.","journal-title":"Breast Cancer Res Treat"},{"issue":"7","key":"5728_CR38","doi-asserted-by":"publisher","first-page":"e354","DOI":"10.1016\/S1470-2045(19)30317-1","volume":"20","author":"S Hernot","year":"2019","unstructured":"Hernot S, van Manen L, Debie P, Mieog JSD, Vahrmeijer AL. Latest developments in molecular tracers for fluorescence image-guided cancer surgery. Lancet Oncol. 2019;20(7):e354\u201367. https:\/\/doi.org\/10.1016\/S1470-2045(19)30317-1.","journal-title":"Lancet Oncol"},{"issue":"9","key":"5728_CR39","doi-asserted-by":"publisher","first-page":"507","DOI":"10.1038\/nrclinonc.2013.123","volume":"10","author":"AL Vahrmeijer","year":"2013","unstructured":"Vahrmeijer AL, Hutteman M, van der Vorst JR, van de Velde CJH, Frangioni JV. Image-guided cancer surgery using near-infrared fluorescence. Nat Rev Clin Oncol. 2013;10(9):507\u201318. https:\/\/doi.org\/10.1038\/nrclinonc.2013.123.","journal-title":"Nat Rev Clin Oncol"},{"key":"5728_CR40","doi-asserted-by":"publisher","first-page":"2250","DOI":"10.1158\/0008-5472.CAN-10-2277","volume":"71","author":"SI Rudnick","year":"2011","unstructured":"Rudnick SI, Lou J, Shaller CC, Tang Y, Klein-Szanto AJP, Weiner LM, et al. Influence of Affinity and Antigen internalization on the Uptake and Penetration of Anti-HER2 antibodies in solid tumors. Cancer Res. 2011;71:2250\u20139.","journal-title":"Cancer Res"},{"key":"5728_CR41","doi-asserted-by":"publisher","first-page":"20214","DOI":"10.1038\/s41598-023-47537-3","volume":"13","author":"RE Sever","year":"2023","unstructured":"Sever RE, Rosenblum LT, Reyes-M\u00fagica M, Edwards WB, Malek MM, Kohanbash G. Survival following complete resection of neuroblastoma in novel orthotopic rat xenograft model. Sci Rep. 2023;13:20214.","journal-title":"Sci Rep"},{"key":"5728_CR42","doi-asserted-by":"publisher","first-page":"17667","DOI":"10.1038\/s41598-020-74464-4","volume":"10","author":"LM Wellens","year":"2020","unstructured":"Wellens LM, Deken MM, Sier CFM, Johnson HR, de la Jara Ortiz F, Bhairosingh SS, et al. Anti-GD2-IRDye800CW as a targeted probe for fluorescence-guided surgery in neuroblastoma. Sci Rep. 2020;10:17667.","journal-title":"Sci Rep"},{"key":"5728_CR43","first-page":"404","volume":"31","author":"HM Ameis","year":"2016","unstructured":"Ameis HM, Drenckhan A, Freytag M, Izbicki JR, Supuran CT, Reinshagen K, et al. Carbonic anhydrase IX correlates with survival and is a potential therapeutic target for neuroblastoma. J Enzyme Inhib Med Chem. 2016;31:404\u20139.","journal-title":"J Enzyme Inhib Med Chem"},{"key":"5728_CR44","doi-asserted-by":"publisher","first-page":"621","DOI":"10.1097\/00000658-200205000-00003","volume":"235","author":"S Kim","year":"2002","unstructured":"Kim S, Hu W, Kelly D, Hellmich M, Evers M, Chung DH. Gastrin-releasing peptide is a growth factor for human neuroblastomas. Ann Surg. 2002;235:621\u201330.","journal-title":"Ann Surg"},{"issue":"8","key":"5728_CR45","doi-asserted-by":"publisher","first-page":"2179","DOI":"10.1158\/1078-0432.CCR-20-3909","volume":"27","author":"AL Yu","year":"2021","unstructured":"Yu AL, Gilman AL, Ozkaynak MF, et al. Long-term follow-up of a phase III study of ch14.18 (Dinutuximab)\u2009+\u2009cytokine immunotherapy in children with high-risk neuroblastoma: COG study ANBL0032. Clin Cancer Res. 2021;27(8):2179\u201389. https:\/\/doi.org\/10.1158\/1078-0432.CCR-20-3909.","journal-title":"Clin Cancer Res"},{"issue":"1","key":"5728_CR46","doi-asserted-by":"publisher","first-page":"17667","DOI":"10.1038\/s41598-020-74464-4","volume":"10","author":"LM Wellens","year":"2020","unstructured":"Wellens LM, Deken MM, Sier CFM, et al. Anti-GD2-IRDye800CW as a targeted probe for fluorescence-guided surgery in neuroblastoma. Sci Rep. 2020;10(1):17667. https:\/\/doi.org\/10.1038\/s41598-020-74464-4.","journal-title":"Sci Rep"},{"key":"5728_CR47","doi-asserted-by":"publisher","first-page":"e354","DOI":"10.1016\/S1470-2045(19)30317-1","volume":"20","author":"S Hernot","year":"2019","unstructured":"Hernot S, van Manen L, Debie P, Mieog JSD, Vahrmeijer AL. Latest developments in molecular tracers for fluorescence image-guided cancer surgery. Lancet Oncol. 2019;20:e354\u201367.","journal-title":"Lancet Oncol"},{"key":"5728_CR48","doi-asserted-by":"publisher","first-page":"507","DOI":"10.1038\/nrclinonc.2013.123","volume":"10","author":"AL Vahrmeijer","year":"2013","unstructured":"Vahrmeijer AL, Hutteman M, van der Vorst JR, van de Velde CJH, Frangioni JV. Image-guided cancer surgery using near-infrared fluorescence. Nat Rev Clin Oncol. 2013;10:507\u201318.","journal-title":"Nat Rev Clin Oncol"}],"container-title":["Journal of Translational Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12967-024-05728-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12967-024-05728-0\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12967-024-05728-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,10,17]],"date-time":"2024-10-17T13:09:36Z","timestamp":1729170576000},"score":1,"resource":{"primary":{"URL":"https:\/\/translational-medicine.biomedcentral.com\/articles\/10.1186\/s12967-024-05728-0"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,10,15]]},"references-count":48,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2024,12]]}},"alternative-id":["5728"],"URL":"https:\/\/doi.org\/10.1186\/s12967-024-05728-0","relation":{},"ISSN":["1479-5876"],"issn-type":[{"value":"1479-5876","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,10,15]]},"assertion":[{"value":"21 February 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"1 October 2024","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"15 October 2024","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Animal studies were performed in accordance with the protocols approved by the Institutional Animal Care and Use Committee of the University of Pittsburgh (IACUC protocol number: 19126346).","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"A patent has been submitted for <sup>111<\/sup>In-GD2-IR800 (application #63\/382,434 for authors MMM, GK, WBE, and LTR).","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"940"}}